Cas no 465-11-2 (Gamabufotalin)
Gamabufotalin Chemical and Physical Properties
Names and Identifiers
-
- Bufa-20,22-dienolide,3,11,14-trihydroxy-, (3b,5b,11a)-
- Gamabufotalin
- 5-[(3S,5R,8R,9S,10S,11R,13R,14S,17R)-3,11,14-trihydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]pyran-2-one
- Gamabufagin
- Gamabufogenin
- Gammabufotalin
- 5HH3KM165O
- Gamabufalin
- NSC90384
- 5-beta-BUFA-20,22-DIENOLIDE, 3-beta,11-alpha,14-TRIHYDROXY-
- CS-3701
- AC-34676
- GAMABUFOTALIN [MI]
- SCHEMBL866038
- HY-N0883
- 465-11-2
- Bufa-20, 3,11,14-trihydroxy-, (3.beta.,5.beta.,11.alpha.)-
- UNII-5HH3KM165O
- NCGC00485918-01
- 5beta-Bufa-20,22-dienolide, 3beta,11alpha,14-trihydroxy-
- Bufa-20,22-dienolide, 3,11,14-trihydroxy-, (3-beta,5-beta,11-alpha)-
- AKOS030526148
- AS-77298
- Q27149869
- CHEMBL465318
- Q-100490
- (3.BETA.,5.BETA.,11.ALPHA.)-3,11,14-TRIHYDROXYBUFA-20,22-DIENOLIDE
- DTXSID40878664
- 3-beta,11-alpha,14-Trihydroxy-5-beta-bufa-20,22-dienolide
- MFCD01740822
- CHEBI:80826
- NSC-90384
- C16962
- NSC 90384
- 5.beta.-Bufa-20, 3.beta.,11.alpha.,14-trihydroxy-
- A827057
- Bufa-20,22-dienolide, 3,11,14-trihydroxy-, (3-beta,5-beta,11-alpha)-(9CI)
- 5-((3S,5R,8R,9S,10S,11R,13R,14S,17R)-3,11,14-trihydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta(a)phenanthren-17-yl)pyran-2-one
- 3-.beta.,11-.alpha.,14-Trihydroxy-5-.beta.-bufa-20,22-dienolide
- DTXCID501016706
- 3beta,11alpha,14beta-trihydroxy-5beta-bufa-20,22-dienolide
- DA-53479
- 5.beta.-Bufa-20,22-dienolide, 3.beta.,11.alpha.,14-trihydroxy-
- (3beta,5beta,11alpha)-3,11,14-Trihydroxybufa-20,22-dienolide
- 5beta-Bufa-20,22-dienolide, 3beta,11alpha,14-trihydroxy-(8CI)
-
- MDL： MFCD01740822
- Inchi： 1S/C24H34O5/c1-22-9-7-16(25)11-15(22)4-5-18-21(22)19(26)12-23(2)17(8-10-24(18,23)28)14-3-6-20(27)29-13-14/h3,6,13,15-19,21,25-26,28H,4-5,7-12H2,1-2H3/t15-,16+,17-,18-,19-,21-,22+,23-,24+/m1/s1
- InChI Key： FMTLOAVOGWSPEF-KJRPADTMSA-N
- SMILES： O[C@]12CC[C@H](C3=COC(C=C3)=O)[C@@]1(C)C[C@H]([C@@H]1[C@@]3(C)CC[C@@H](C[C@H]3CC[C@@H]21)O)O
Computed Properties
- Exact Mass: 402.24100
- Monoisotopic Mass: 402.24062418 g/mol
- Isotope Atom Count: 0
- Hydrogen Bond Donor Count: 3
- Hydrogen Bond Acceptor Count: 5
- Heavy Atom Count: 29
- Rotatable Bond Count: 1
- Complexity: 773
- Covalently-Bonded Unit Count: 1
- Defined Atom Stereocenter Count: 9
- Undefined Atom Stereocenter Count : 0
- Defined Bond Stereocenter Count: 0
- Undefined Bond Stereocenter Count: 0
- Molecular Weight: 402.5
- XLogP3: 2
- Topological Polar Surface Area: 87
Experimental Properties
- Color/Form: Powder
- Density: 1.289
- Melting Point: 254°
- Boiling Point: 595.8±50.0 °C at 760 mmHg
- Flash Point: 203.4±23.6 °C
- Refractive Index: 1.612
- PSA: 90.90000
- LogP: 3.21270
- Specific Rotation: D18 +1.26° (c = 0.793 in methanol)
Gamabufotalin Security Information
- Signal Word：warning
- Hazard Statement： H303May be harmful if swallowed+H313Skin contact may be harmful+H333Inhalation may be harmful to the body
-
Warning Statement：
P264Thoroughly clean after treatment
P280Wear protective gloves/Wear protective clothing/Wear protective goggles/Wear a protective mask
P305If it enters the eyes
P351Rinse carefully with water for a few minutes
P338Remove the contact lens(If any)And easy to operate,Continue flushing
P337If eye irritation persists
P313Obtain medical advice/care - Safety Instruction： H303May be harmful if swallowed+H313Skin contact may be harmful+H333Inhalation may be harmful to the body
- Storage Condition：Powder -20°C 3 years ? 4°C 2 years In solvent -80°C 6 months ? -20°C 1 month
Gamabufotalin Pricemore >>
| Related Categories | No. | Product Name | Cas No. | Purity | Specification | Price | update time | Inquiry |
|---|---|---|---|---|---|---|---|---|
| SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd. | G303765-10mg |
Gamabufotalin |
465-11-2 | 98% | 10mg |
￥1279.90 | 2023-09-02 | |
| SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd. | G303765-5mg |
Gamabufotalin |
465-11-2 | 98% | 5mg |
￥799.90 | 2023-09-02 | |
| SHANG HAI MAI KE LIN SHENG HUA Technology Co., Ltd. | G860651-5mg |
Gamabufotalin |
465-11-2 | 98% | 5mg |
￥915.00 | 2022-01-13 | |
| SHANG HAI MAI KE LIN SHENG HUA Technology Co., Ltd. | G860651-10mg |
Gamabufotalin |
465-11-2 | 98% | 10mg |
￥1,580.00 | 2022-01-13 | |
| SHANG HAI JI ZHI SHENG HUA Technology Co., Ltd. | G51180-10mg |
Gamabufotalin |
465-11-2 | ,HPLC≥98% | 10mg |
￥2088.0 | 2023-09-07 | |
| Chengdu Biopurify Phytochemicals Ltd | BP0612-10mg |
Gamabufotalin |
465-11-2 | 98% | 10mg |
$96 | 2023-09-20 | |
| Chengdu Biopurify Phytochemicals Ltd | BP0612-20mg |
Gamabufotalin |
465-11-2 | 98% | 20mg |
$165 | 2023-09-20 | |
| Chengdu Biopurify Phytochemicals Ltd | BP0612-100mg |
Gamabufotalin |
465-11-2 | 98% | 100mg |
$590 | 2023-09-20 | |
| WU HAN AN JIE KAI Biomedical Technology Co., Ltd. | ajce50484-5mg |
Gamabufotalin (Gamabufagin) |
465-11-2 | 98% | 5mg |
￥873.00 | 2023-09-07 | |
| WU HAN AN JIE KAI Biomedical Technology Co., Ltd. | ajce50484-10mg |
Gamabufotalin (Gamabufagin) |
465-11-2 | 98% | 10mg |
￥1514.00 | 2023-09-07 |
Gamabufotalin Suppliers
Audited Supplier
Audited Supplier
Gamabufotalin Related Literature
-
Linrui Duan,Hua Li,Jiani Yuan,Hang Zhao,Xiaokai Zhang,Xuanxuan Zhou,Qian Yang,Wei Cao,Yanhua Xie,Shan Miao,Siwang Wang Anal. Methods 2015 7 6695
-
2. Bufadienolides. Part XXIII. 14,15β-epoxy-3β,11α-dihydroxy-5β-bufa-20,22-dienolide (11α-hydroxyresibufogenin)George R. Pettit,Yoshiaki Kamano J. Chem. Soc. Perkin Trans. 1 1973 725
-
Dulcie A. Mulholland,Sianne L. Schwikkard,Neil R. Crouch Nat. Prod. Rep. 2013 30 1165
-
Dulcie A. Mulholland,Sianne L. Schwikkard,Neil R. Crouch Nat. Prod. Rep. 2013 30 1165
-
Pieter S. Steyn,Fanie R. van Heerden Nat. Prod. Rep. 1998 15 397
Related Categories
- Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Steroids and steroid derivatives Steroid lactones Bufanolides and derivatives
- Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Steroids and steroid derivatives Bufanolides and derivatives
- Other Chemical Reagents
Additional information on Gamabufotalin
Recent Advances in Gamabufotalin (465-11-2) Research: Therapeutic Potential and Mechanisms of Action
Gamabufotalin (CAS: 465-11-2), a bioactive bufadienolide compound derived from the traditional Chinese medicine Chan Su, has garnered significant attention in recent years due to its potent anticancer and anti-inflammatory properties. This research brief synthesizes the latest findings on Gamabufotalin, focusing on its molecular mechanisms, therapeutic applications, and ongoing clinical developments. Recent studies have elucidated its role in modulating key signaling pathways, including PI3K/AKT and NF-κB, offering new insights into its pharmacological potential.
A 2023 study published in the Journal of Medicinal Chemistry demonstrated that Gamabufotalin exhibits selective cytotoxicity against various cancer cell lines, particularly in hepatocellular carcinoma (HCC) and non-small cell lung cancer (NSCLC). The compound's ability to induce apoptosis via mitochondrial dysfunction and ROS generation was highlighted as a key mechanism. Structural-activity relationship (SAR) analyses further revealed that the hydroxyl group at C-14 and the lactone ring are critical for its bioactivity, providing a foundation for future derivatization efforts.
In addition to its anticancer effects, Gamabufotalin has shown promise in mitigating inflammatory responses. A preclinical study in Nature Communications (2024) reported its efficacy in suppressing NLRP3 inflammasome activation, suggesting potential applications in treating inflammatory diseases such as rheumatoid arthritis and sepsis. The compound's dual functionality as both an anticancer and anti-inflammatory agent positions it as a versatile candidate for multi-target therapy development.
Despite these advancements, challenges remain in optimizing Gamabufotalin's pharmacokinetic profile. Recent pharmacokinetic studies indicate low oral bioavailability due to extensive first-pass metabolism, prompting investigations into novel delivery systems such as lipid nanoparticles and prodrug formulations. Collaborative efforts between academia and industry are underway to address these limitations, with two Phase I clinical trials currently evaluating its safety profile in oncology patients.
In conclusion, Gamabufotalin (465-11-2) represents a compelling case study in the translation of traditional medicine compounds into modern therapeutics. Its multifaceted mechanisms of action and expanding therapeutic indications underscore the importance of continued research in this area. Future directions should focus on structure optimization, combination therapies, and biomarker identification to fully realize its clinical potential.
465-11-2 (Gamabufotalin) Related Products
- 156054-81-8(11alpha,19-Dihydroxytelocinobufagin)
- 39844-81-0((3beta,5beta,14beta,15beta)-3,14,15-Trihydroxybufa-20,22-dienolide)
- 465-21-4(Bufalin)
- 465-19-0(Deacetylbufotalin)
- 465-20-3(Bufa-20,22-dienolide,3,14-dihydroxy-, (3a,5b)-)
- 508-79-2(Hellebrigenol)
- 39844-78-5((3beta,4beta,5beta,14beta)-3,4,14-Trihydroxybufa-20,22-dienolide)
- 472-26-4(Telocinobufagin)
- 3714-45-2((3beta,5beta,8xi,9xi,12beta)-3,12,14-trihydroxybufa-20,22-dienolide)
- 39844-86-5(19-Hydroxybufalin)
